Lazard Capital Markets Life Sciences Conference to Webcast Alkermes' Corporate Presentation.CAMBRIDGE, Mass. -- Alkermes, Inc. (Nasdaq: ALKS ALKS Alkermes, Inc. (stock symbol) ) announced today that its corporate presentation will be webcast live by Lazard Capital Markets Lazard Capital Markets is a New York-based investment bank founded in 2005 in a spin-off from its parent Lazard. Lazard Capital Markets focuses its activities on equity research, sales and trading; fixed income and convertible bond sales and trading; and securities on Wednesday, November 30, 2005 at 8:00 a.m. EST EST electroshock therapy. EST abbr. electroshock therapy . The presentation will be webcast from The Palace Hotel in New York New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of and may be accessed under the investor relation's tab at www.alkermes.com. The presentation will be archived for 14 days. Alkermes, Inc. is a pharmaceutical company that develops products based on sophisticated drug delivery technologies to enhance therapeutic outcomes in major diseases. The Company's lead commercial product, RISPERDAL CONSTA(R) ((risperidone) long-acting injection), is the first and only long-acting atypical antipsychotic The atypical anti-psychotics (also known as second generation anti-psychotics) are a class of prescription medications used to treat psychiatric conditions. Some atypical anti-psychotics are FDA approved for use in the treatment of schizophrenia. medication approved for use in schizophrenia, and is marketed worldwide by Janssen-Cilag ("Janssen"), a wholly owned division of Johnson & Johnson. The Company's lead proprietary product candidate, VIVITREX(R) (naltrexone naltrexone /nal·trex·one/ (nal-trek´son) an opioid antagonist used as the hydrochloride salt in treatment of opioid or alcohol abuse. nal·trex·one n. An endorphin and narcotic antagonist. long-acting injection), is being developed as a once-monthly injection for the treatment of alcohol dependence. The Company has a pipeline of extended-release injectable products and pulmonary drug products based on its proprietary technology and expertise. Alkermes' product development strategy is twofold: the Company partners its proprietary technology systems and drug delivery expertise with several of the world's finest pharmaceutical companies and it also develops novel, proprietary drug candidates for its own account. The Company's headquarters are in Cambridge, Massachusetts, and it operates research and manufacturing facilities in Massachusetts and Ohio. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion